Ruben Ekbråten (37) has been appointed as the new Chief Executive
Officer (CEO) of DiaGenic ASA effective from 1st February 2014. The
appointment is temporary for 2 months. Ruben Ekbråten holds the position
as Chief Financial Officer (CFO) in DiaGenic ASA. In addition to his 6
years tenure at DiaGenic he has international experience from several
positions within finance at GE Healthcare. Ruben Ekbråten holds an MBA
from Heriot Watt University, and a BBA from Norwegian School of
Management.
"The Board of DiaGenic are very pleased that Ruben Ekbråten has accepted
to be appointed acting CEO. This is an important phase for the company,
and the constitution of Ruben Ekbråten ensure competence and continuity
in safeguarding the company's affairs" says Chairman Hanne S. Holen.
With reference to the stock exchange notice on 10th January the Company
announced reduction in payment obligations based on inter alia earlier
termination of the facility lease. As a consequence, the Company will
move to new facilities effective from 1st February 2014. The new address
for DiaGenic ASA is:
Sjølyst plass 2, 0278 Oslo, Norway
Contact:
Hanne Skaarberg Holen, Chairman of the Board, +47 982 94 591